How much cash does Sana Biotechnology generate?

Sana Biotechnology (SANA) generated -$132.6M in operating cash flow over the trailing twelve months.

What is Sana Biotechnology's free cash flow?

After $1.3M of capital expenditures, Sana Biotechnology's free cash flow was -$133.6M over the trailing twelve months, up 40.3% year over year.

Where does Sana Biotechnology's cash flow data come from?

Every line is extracted from Sana Biotechnology's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Sana Biotechnology SANA Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$241.99M-16.0%	-$244.17M+8.5%	-$234.41M+23.3%	-$252.18M-2.6%	-$208.67M+32.6%
Depreciation and amortization	——	——	——	——	——
Stock-based compensation	$24.1M-32.3%	$25.46M-32.4%	$25.56M-34.7%	$30.86M-17.5%	$35.61M-0.7%
Change in accounts payable	——	——	——	——	-$1.78M—
Change in accrued liabilities	——	——	——	-$15.59M—	——
Change in other assets	——	——	——	——	——
Other working capital changes	$10.32M+8.7%	$10.98M-1.1%	$11.1M-1.1%	$12.01M-0.7%	$9.49M-37.9%
Non-cash operating lease expense	$9.41M+9.7%	$9.17M-5.3%	$8.96M-16.5%	$8.76M-26.4%	$8.58M-35.3%
Change in fair value of contingent consideration	——	——	——	$5.51M—	-$4.16M—
Net cash from operating activities	-$132.55M+35.7%	-$143.83M+35.5%	-$158.35M+30.5%	-$180.74M+24.6%	-$206.18M+14.1%
Capital expenditures	——	——	——	——	$17.72M-47.4%
Proceeds from sale of businesses	$1.43M+464%	$1.43M—	$771K—	$635K—	$253K—
Net cash from investing activities	-$7.4M—	-$40.24M—	$23.35M—	——	——
Proceeds from issuance of common stock	$126.21M—	$127.28M—	——	——	——
Net cash from financing activities	$127.62M+790%	$128.73M-35.6%	$111.73M-44.4%	$4.27M-97.9%	$14.33M-93.4%
Net increase (decrease) in cash	——	——	——	——	——
Contingent consideration fair value adjustments	——	——	——	$5.51M—	-$4.16M—
Change In Fair Value Of Success Payment Liabilities	$12.28M—	$14.68M—	-$1.39M—	——	——
Depreciation	——	——	——	——	——
Accrued expenses and other liabilities	——	——	——	-$15.59M—	——
Increase Decrease In Operating Lease Right Of Use Assets And Liabilities	$5.38M+222%	$3M+132%	-$211K+98.7%	-$1.83M+89.2%	-$4.43M+73.6%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——	——
Operating lease right-of-use asset amortization	$9.41M+9.7%	$9.17M-5.3%	$8.96M-16.5%	$8.76M-26.4%	$8.58M-35.3%
Other Noncash Income (Expense)	$10.32M+8.7%	$10.98M-1.1%	$11.1M-1.1%	$12.01M-0.7%	$9.49M-37.9%
Proceeds from disposition of property, plant and equipment/other	$1.43M+464%	$1.43M—	$771K—	$635K—	$253K—
Payments Of Stock Issuance Costs	——	——	——	——	——
Principal Payments Net For Tenant Improvement Loan	——	——	——	——	——
Proceeds from exercises of stock options and other stock issuances	$1.61M-77.7%	$2.68M-75.7%	$2.32M-80.7%	$4.1M-60.1%	$7.2M-22.7%
Cash Received For Tenant Improvement Allowances	——	——	——	——	$2.28M—
Derecognition Of Operating Lease Right Of Use Assets For Lease Termination And Modification	——	-$2.72M+62.5%	-$3.86M+57.1%	-$4.99M+53.5%	-$6.13M+50.9%
Free cash flow	-$133.64M+40.3%	-$144.77M+43.6%	-$158.85M+42.2%	-$185.29M+35.0%	-$223.9M+18.2%
Free cash flow	-$133.64M+40.3%	-$144.77M+43.6%	-$158.85M+42.2%	-$185.29M+35.0%	-$223.9M+18.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Sana Biotechnology generate?: Sana Biotechnology (SANA) generated -$132.6M in operating cash flow over the trailing twelve months.
What is Sana Biotechnology's free cash flow?: After $1.3M of capital expenditures, Sana Biotechnology's free cash flow was -$133.6M over the trailing twelve months, up 40.3% year over year.
Where does Sana Biotechnology's cash flow data come from?: Every line is extracted from Sana Biotechnology's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.